We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+63.68%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.94B
AUM Growth
+$727M
Cap. Flow
+$234M
Cap. Flow %
7.95%
Top 10 Hldgs %
50.17%
Holding
105
New
24
Increased
24
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$134M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$118M
3
TERN
Terns Pharmaceuticals
TERN
+$104M
4
ABVX
Abivax
ABVX
+$98.2M
5
MRK icon
Merck
MRK
+$72.7M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$104M
2
ASND icon
Ascendis Pharma A/S
ASND
+$87.8M
3
FOLD
Amicus Therapeutics
FOLD
+$76.8M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$70.3M
5
BDX icon
Becton Dickinson
BDX
+$60.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
101
Arcus Biosciences
RCUS
$3.64B
– –
-250,000
Closed -$3.4M
REGN icon
102
Regeneron Pharmaceuticals
REGN
$80.8B
– –
-25,000
Closed -$14.1M
VTYX
103
DELISTED
Ventyx Biosciences
VTYX
– –
-2,050,000
Closed -$6.38M
TRAW icon
104
Traws Pharma
TRAW
$8.1M
– –
-150,000
Closed -$278K
TVRD
105
Tvardi Therapeutics
TVRD
$23.4M
– –
-167,000
Closed -$6.51M
1 2 3 4
5

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $3.52B AUM 52.63% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Vestal Point Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Vestal Point Capital held 105 positions worth $2.94B, up 33% from $2.21B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Vestal Point Capital deployed $234M of net new capital in Q4 2025, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Terns Pharmaceuticals: 4,500,000 shares worth $182M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $104M trimmed.

  • Vestal Point Capital's largest Q4 2025 buy was Terns Pharmaceuticals: 4,500,000 shares worth $182M.
  • Vestal Point Capital added most to Arcellx in Q4 2025, an estimated $134M increase.
  • Vestal Point Capital's biggest Q4 2025 reduction was Nuvalent, cutting an estimated $104M.
  • Vestal Point Capital fully exited Amicus Therapeutics in Q4 2025, selling an estimated $76.8M.
  • Vestal Point Capital's ten largest holdings make up 50% of its $2.94B portfolio in Q4 2025.
  • Vestal Point Capital opened 24 new positions and closed 29 in Q4 2025.
  • Vestal Point Capital's portfolio value rose 33% quarter-over-quarter to $2.94B.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.